Skip to main content
Log in

High liposomal doxorubicin tumour tissue distribution, as determined by radiopharmaceutical labelling with 99mTc-LD, is associated with the response and survival of patients with unresectable pleural mesothelioma treated with a combination of liposomal doxorubicin and cisplatin

  • Short Communication
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

Background

There are currently no available biomarkers for advanced pleural mesothelioma that determine which patients could benefit from a specific chemotherapy regimen.

Methods

Based on the results of a previously published phase II study, we associated the 99mTechnetium-labelled liposomal doxorubicin (99mTc-LD) uptake value (75 % cut-off) with the response rate, progression-free survival and overall survival of patients treated with a combination of liposomal doxorubicin and cisplatin.

Results

Patients with tumours exhibiting increased 99mTc-LD uptake showed better response rates, progression-free survival and overall survival than those exhibiting lower uptake 73.3 versus 15 % (p < 0.001); 6.9 versus 3.2 months (p = 0.033) and 23 versus 6.6 months (p = 0.001), respectively.

Conclusion

99mTc-DL uptake in tumour tissue could define a set of patients who would benefit from this chemotherapy regimen.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Aguilar-Madrid G, Robles-Pérez E, Juárez-Pérez CA, Alvarado-Cabrero I, Rico-Méndez FG, Javier KG (2010) Case–control study of pleural mesothelioma in workers with social security in Mexico. Am J Ind Med 53(3):241–251. doi:10.1002/ajim.20780

    PubMed  Google Scholar 

  2. Ardizzoni A, Rosso R, Salvati F, Fusco V, Cinquegrana A, De Palma M, Serrano J, Pennucci MC, Soresi E, Crippa M, Gulisano M, Castagneto B, Scagliotti G, Rinaldi M (1991) Activity of doxorubicin and cisplatin combination chemotherapy in patients with diffuse malignant pleural mesothelioma. An Italian Lung Cancer Task Force (FONICAP) Phase II study. Cancer 67(12):2984–2987

    Article  CAS  PubMed  Google Scholar 

  3. Arrieta Ó, Medina LA, Estrada-Lobato E, Hernández-Pedro N, Villanueva-Rodríguez G, Martínez-Barrera L, Macedo EO, López-Rodríguez V, Motola-Kuba D, Corona-Cruz JF (2012) First-line chemotherapy with liposomal doxorubicin plus cisplatin for patients with advanced malignant pleural mesothelioma: phase II trial. Br J Cancer 106(6):1027–1032. doi:10.1038/bjc.2012.44

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  4. Baas P, van Meerbeeck J, Groen H, Schouwink H, Burgers S, Daamen S, Giaccone G (2000) Caelyx™ in malignant mesothelioma: a phase II EORTC study. Ann Oncol 11(6):697–700

    Article  CAS  PubMed  Google Scholar 

  5. Bénard F, Sterman D, Smith RJ, Kaiser LR, Albelda SM, Alavi A (1998) Metabolic imaging of malignant pleural mesothelioma with fluorodeoxyglucose positron emission tomography. Chest 114(3):713–722

    Article  PubMed  Google Scholar 

  6. Head HW, Dodd GD 3rd, Bao A, Soundararajan A, Garcia-Rojas X, Prihoda TJ, McManus LM, Goins BA, Santoyo CA, Phillips WT (2010) Combination radiofrequency ablation and intravenous radiolabeled liposomal doxorubicin: imaging and quantification of increased drug delivery to tumors. Radiology 255(2):405–414. doi:10.1148/radiol.10090714

    Article  PubMed Central  PubMed  Google Scholar 

  7. Health and Safety Executive (2013) Mesothelioma in Great Britain 2013. Mesothelioma mortality in Great Britain 1968–2011. Health and Safety Executive, UK

    Google Scholar 

  8. Henss H, Fiebig HH, Schildge J, Arnold H, Hasse J (1988) Phase-II study with the combination of cisplatin and doxorubicin in advanced malignant mesothelioma of the pleura. Onkologie 11(3):118–120

    Article  CAS  PubMed  Google Scholar 

  9. Ji S, Zheng Y, Shao G, Zhou Y, Liu S (2013) Integrin αvβ3-targeted radiotracer (99m)Tc-3P-RGD2 useful for noninvasive monitoring of breast tumor response to antiangiogenic linifanib therapy but not anti-integrin αvβ3 RGD2 therapy. Theranostics 3(11):816–830. doi:10.7150/thno.6989

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  10. Kao SC, Lee K, Klebe S, Henderson D, McCaughan B, Vardy J, Clarke S, van Zandwijk N (2013) Excision repair cross complementation group 1 and thymidylate synthase expression in mesothelioma patients. Clin Lung Cancer 14(2):164–171. doi:10.1016/j.cllc.2012.09.003

    Article  CAS  PubMed  Google Scholar 

  11. Kim ES, Lee JJ, He G, Chow CW, Fujimoto J, Kalhor N, Swisher SG, Wistuba II, Stewart DJ, Siddik ZH (2012) Tissue platinum concentration and tumor response in non-small-cell lung cancer. J Clin Oncol 30(27):3345–3352. doi:10.1200/JCO.2011.40.8120

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  12. Lee CW, Murray N, Anderson H, Rao SC, Bishop W (2009) Outcomes with first-line platinum-based combination chemotherapy for malignant pleural mesothelioma: a review of practice in British Columbia. Lung Cancer 64(3):308–313. doi:10.1016/j.lungcan.2008.09.008

    Article  PubMed  Google Scholar 

  13. Lustgarten DE, Deshpande C, Aggarwal C, Wang LC, Saloura V, Vachani A, Wang LP, Litzky L, Feldman M, Creaney J, Nowak AK, Langer C, Inghilleri S, Stella G, Albelda SM (2013) Thymidylate synthase and folyl-polyglutamate synthase are not clinically useful markers of response to pemetrexed in patients with malignant pleural mesothelioma. J Thorac Oncol 8(4):469–477. doi:10.1097/JTO.0b013e318283da3e

    Article  CAS  PubMed  Google Scholar 

  14. Arrieta O, López-Macías D, Mendoza-García VO, Bacon-Fonseca L, Muñoz-Montalvo W, Macedo-Pérez EO,Muñiz-Hernández S, Blake-Cerda M, Corona-Cruz JF (2014) A phase II trial of prolonged, continuous infusion of low-dose gemcitabine plus cisplatin in patients with advanced malignant pleural mesothelioma. Cancer Chemother Pharmacol 73(5):975–982. doi:10.1007/s00280-014-2429-5

  15. Pinto C, Novello S, Torri V, Ardizzoni A, Betta PG, Bertazzi PA, Casalini GA, Fava C, Fubini B, Magnani C, Mirabelli D, Papotti M, Ricardi U, Rocco G, Pastorino U, Tassi G, Trodella L, Zompatori M, Scagliotti G (2013) Second Italian consensus conference on malignant pleural mesothelioma: state of the art and recommendations. Cancer Treat Rev 39(4):328–339. doi:10.1016/j.ctrv.2012.11.004

    Article  PubMed  Google Scholar 

  16. Ralli M, Tourkantonis I, Makrilia N, Gkini E, Kotteas E, Gkiozos I, Katirtzoglou N, Syrigos K (2009) Docetaxel plus gemcitabine as first-line treatment in malignant pleural mesothelioma: a single institution phase II study. Anticancer Res 29(8):3441–3444

    CAS  PubMed  Google Scholar 

  17. Sharif S, Zahid I, Routledge T, Scarci M (2011) Does positron emission tomography offer prognostic information in malignant pleural mesothelioma? Interact CardioVasc Thorac Surg 12(5):806–811. doi:10.1510/icvts.2010.255901

    Article  PubMed  Google Scholar 

  18. Sørensen JB, Frank H, Palshof T (2008) Cisplatin and vinorelbine first-line chemotherapy in non-resectable malignant pleuralmesothelioma. Br J Cancer 99(1):44–50. doi:10.1038/sj.bjc.6604421

    Article  PubMed Central  PubMed  Google Scholar 

  19. van Meerbeeck JP, Gaafar R, Manegold C, Van Klaveren RJ, Van Marck EA, Vincent M, Legrand C, Bottomley A, Debruyne C, Giaccone G (2005) European Organisation for Research and Treatment of Cancer Lung Cancer Group; National Cancer Institute of Canada Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol 28:6881–6889

    Article  Google Scholar 

  20. Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, Gatzemeier U, Boyer M, Emri S, Manegold C, Niyikiza C, Paoletti P (2003) Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21(14):2636–2644

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Oscar Arrieta.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Arrieta, O., Medina, LA., Estrada-Lobato, E. et al. High liposomal doxorubicin tumour tissue distribution, as determined by radiopharmaceutical labelling with 99mTc-LD, is associated with the response and survival of patients with unresectable pleural mesothelioma treated with a combination of liposomal doxorubicin and cisplatin. Cancer Chemother Pharmacol 74, 211–215 (2014). https://doi.org/10.1007/s00280-014-2477-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-014-2477-x

Keywords

Navigation